Web11 mrt. 2024 · Ionis Pharmaceuticals has a 1 year low of $31.46 and a 1 year high of $48.82. The firm has a market capitalization of $4.97 billion, a price-to-earnings ratio of -18.29 and a beta of 0.57. The company has a debt-to-equity ratio of 2.06, a current ratio of 7.07 and a quick ratio of 7.00. Web10 mei 2014 · View Archit Rastogi, PhD’S profile on LinkedIn, the world’s largest professional community. Archit has 8 jobs listed on their profile. …
Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down
Web9 nov. 2024 · Ionis Pharmaceuticals , which belongs to the Zacks Medical - Drugs … Web3 nov. 2024 · Ionis' revenue was comprised of the following (amounts in millions): In the … inclusive halloween tips
Ionis reports fourth quarter and full year 2024 financial …
Web13 apr. 2024 · According to the data, the short interest in Amarin Corporation plc (AMRN) stood at 4.65% of shares outstanding as of Mar 14, 2024; the number of short shares registered in Feb 14, 2024 reached 12.07 million. The stock has risen by 12.40% since the beginning of the year, thereby showing the potential of a further growth. Web11 apr. 2024 · Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Equal-Weight and raises the price target from $40 to $42. WebIonis annonce des résultats positifs à 66 semaines de l'étude de phase 3 sur l'Eplonter.. 03/23: Ionis Pharmaceuticals annonce que son candidat médicament contre la SLA reçoit un souti.. 03/07: Ionis Pharmaceuticals déclare que la FDA a accepté d'examiner sa demande pour le candid.. 03/07 inclusive handicap